The 36-month beta value for SLXN is also noteworthy at 0.12. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLXN is 6.81M, and at present, short sellers hold a 23.46% of that float. The average trading volume of SLXN on February 25, 2025 was 11.35M shares.
SLXN) stock’s latest price update
The stock price of Silexion Therapeutics Corp (NASDAQ: SLXN) has jumped by 63.97 compared to previous close of 0.75. Despite this, the company has seen a gain of 19.40% in its stock price over the last five trading days. globenewswire.com reported 2025-02-25 that Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks
SLXN’s Market Performance
SLXN’s stock has risen by 19.40% in the past week, with a monthly rise of 85.35% and a quarterly drop of -58.98%. The volatility ratio for the week is 14.60% while the volatility levels for the last 30 days are 22.93% for Silexion Therapeutics Corp The simple moving average for the last 20 days is -10.40% for SLXN’s stock, with a simple moving average of -96.74% for the last 200 days.
SLXN Trading at -29.67% from the 50-Day Moving Average
After a stumble in the market that brought SLXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.99% of loss for the given period.
Volatility was left at 22.93%, however, over the last 30 days, the volatility rate increased by 14.60%, as shares surge +71.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.50% lower at present.
During the last 5 trading sessions, SLXN fell by -3.62%, in comparison to the 20-day moving average, which settled at $1.3608. In addition, Silexion Therapeutics Corp saw -38.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLXN
The total capital return value is set at 25.0. Equity return is now at value -3.78, with -284.50 for asset returns.
Based on Silexion Therapeutics Corp (SLXN), the company’s capital structure generated -16.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.56. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is 302.41.
Currently, EBITDA for the company is -4.64 million with net debt to EBITDA at -0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
In summary, Silexion Therapeutics Corp (SLXN) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
